-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

A Case-based Workshop: Clinical and Laboratory Aspects of Hemophilia and Thrombosis

Sponsor: Mayo Clinic
Program: Satellite Symposia
Hematology Disease Topics & Pathways:
Diseases, Bleeding and Clotting
Friday, December 4, 2020: 7:00 AM-10:00 AM
Rajiv K. Pruthi, M.B.B.S, Mayo Clinic, Mayo Clinic and Dong Chen, M.D., Ph.D., Mayo Clinic
Pruthi: Bayer Healthcare: Honoraria; Genentech Inc.: Honoraria; CSL Behring: Honoraria; HEMA Biologics: Honoraria; Instrumentation Laboratory: Honoraria; Merck: Honoraria.
Rajiv K. Pruthi, M.B.B.S, Mayo Clinic , Anand Padmanabhan, M.B.B.S., Ph.D., Mayo Clinic , Dong Chen, M.D., Ph.D., Mayo Clinic and Ana I Casanegra, M.D., Mayo Clinic
Pruthi: Genentech Inc.: Honoraria; Bayer Healthcare: Honoraria; HEMA Biologics: Honoraria; Instrumentation Laboratory: Honoraria; Merck: Honoraria; CSL Behring: Honoraria. Padmanabhan: Retham Technologies: Current equity holder in private company, Patents & Royalties: Patents pending; Veralox Therapeutics: Membership on an entity's Board of Directors or advisory committees; Versiti Blood Research Institute: Patents & Royalties: Issued patents and pending patents; Mayo Clinic: Patents & Royalties: Invention disclosure filed.
This program’s overall objective is to inform participants about emerging diagnostic and therapeutic aspects of bleeding and thrombotic disorders. Topics discussed will include choosing the right type of factor assays for monitoring newer factor and non-factor products for hemophilia management, optimal role of newer technologies like next generation sequencing for diagnosis of coagulation disorders, optimal laboratory evaluation of inherited platelet disorders, update on recent advances in the diagnosis of heparin induced thrombocytopenia and role of measuring direct acting oral anticoagulants.

Using test-ordering algorithms based on data derived from the Mayo Clinic Special Coagulation Laboratory practice and the literature, we will illustrate how costly and unnecessary biochemical, phenotypic and genetic testing can be avoided in the participants’ practices while enhancing highest quality medical care.

See more of: Satellite Symposia